Non-Resectable Locally Advanced Pancreatic Cancer (LAPC) research hub

A Prospective, Randomized, Controlled, Multinational, Phase 2/3, Open-Label Trial to Evaluate the Efficacy and Safety of SIL204-SL Administered as an Integrated Therapeutic Regimen in Combination with Chemotherapy vs. Chemotherapy Treatment Alone in Participants with Locally Advanced Pancreatic Cancer

This study looks at a new drug, SIL204-SL, combined with standard chemotherapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. Researchers want to find out if adding this new treatment helps people live longer, slows tumour growth, and maintains quality of life compared to chemotherapy alone.